G7 Health Ministers address antibacterial resistance
October 9, 2015 Leave a comment
The G7 Health Ministers discussed antibacterial resistance during the G7-Meeting in Berlin on 8 and 9 October 2015.
The “Berlin Declaration on AMR” includes strong committments to:
- Improve the coordination between global initiatives and joint international efforts encompassing human and animal health, agriculture and the environment.
- National AMR Action Plans will take into account the requirements of the WHO Global Action Plan.
- Support other countries with the development and implementation of their National Action Plans, building global capacity to combat AMR and coordinating activity.
- Three-fold approach to AMR: improving infection prevention and control; conserving the effectiveness of existing and future antimicrobials; engaging in research to optimise such approaches and to develop new antimicrobials, vaccines, treatment alternatives and rapid diagnostic tools.
- Pool the national efforts in order to share best practices and promote the prudent use of antimicrobials among all relevant stakeholders.
- Increase awareness among the general public of the impact of AMR .
- Call on all countries to enforce the availability of antibiotics by prescription only.
- Strengthen antibiotic stewardship programs for professionals.
- Ensure the production of high quality antimicrobials in human and veterinary medicine.
- Strengthen surveillance systems on AMR and antimicrobial consumption.
- Inform research prioritization and encourage the research and development of new antimicrobials, vaccines, alternative treatment options and diagnostics.
- Explore innovative economic incentives to enhance the research and development of new antibiotics, other therapeutic options, and diagnostics, e.g. a global antibiotic research fund and a market entry reward mechanism for truly new antibiotics targeting the most important pathogens and most needed for global public health.
- Explore the feasibility and need of setting up a global antibiotic product development partnership.
- Encourage international cooperation on antimicrobial stewardship and regulatory dialogue on the approval and regulation for antibiotics.
DRIVE-AB supports this initiative and will provide scientific data to inform the decisions regarding antibiotic stewardship (metrics to define the prudent antibiotic use) and innovative economic incentives to encourage research and development of new antibiotics.